Saponin-adjuvanted particulate vaccines for clinical use.
about
The Last Ten Years of Advancements in Plant-Derived Recombinant Vaccines against Hepatitis BBovine neonatal pancytopenia--comparative proteomic characterization of two BVD vaccines and the producer cell surface proteome (MDBK).Advances in the design and delivery of peptide subunit vaccines with a focus on toll-like receptor agonistsChitosan nanoparticles act as an adjuvant to promote both Th1 and Th2 immune responses induced by ovalbumin in miceBlood stage merozoite surface protein conjugated to nanoparticles induce potent parasite inhibitory antibodiesImmunological adjuvant effect of the peptide fraction from the larvae of Musca domestica.Triterpenoid saponins from the roots of Acanthophyllum gypsophiloides Regel.The twenty-year story of a plant-based vaccine against hepatitis B: stagnation or promising prospects?Iron oxide nanoparticles as a clinically acceptable delivery platform for a recombinant blood-stage human malaria vaccine.Intake of korean red ginseng extract and saponin enhances the protection conferred by vaccination with inactivated influenza a virus.Improving vaccines by incorporating immunological coadjuvants.Promising particle-based vaccines in cancer therapy.Delivery systems: a vaccine strategy for overcoming mucosal tolerance?Combinatorial biosynthesis in plants: a (p)review on its potential and future exploitation.Phytol-derived novel isoprenoid immunostimulants.Mesoporous silica nanoparticles as antigen carriers and adjuvants for vaccine delivery.Active ingredients from natural botanicals in the treatment of obesity.Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies.Carbohydrate-based vaccine adjuvants - discovery and development.Vaccination of calves with yeast- and bacterial-expressed paramyosin from the bovine lungworm Dictyocaulus viviparus.Cytotoxic effects of four Caryophyllaceae species extracts on macrophage cell lines.Dry-powder form of chitosan nanospheres containing influenza virus and adjuvants for nasal immunization.Mucosal Adjuvant Potential of Quillaja saponins and Cross-linked Dextran Microspheres, Co-administered with Liposomes Encapsulated with Tetanus Toxoid.[Comparative safety study of two commercialised vaccines against canine babesiosis induced by Babesia canis].Engineering triterpene production in Saccharomyces cerevisiae-beta-amyrin synthase from Artemisia annua.The mucosal adjuvant potential of cross-linked dextran microspheres as dry powder.Preparation and in vivo study of dry powder microspheres for nasal immunization.Evaluation of ISCOM vaccines for mucosal immunization against hepatitis B.Saponins in Madhuca Longifolia as undesirable substances in animal feedEvidence for a Saponin Biosynthesis Pathway in the Body Wall of the Commercially Significant Sea Cucumber Holothuria scabra.Nuclear G protein-coupled oestrogen receptor (GPR30) predicts poor survival in patients with ovarian cancer.Selective Profiling of Saponins from Gypsophila trichotoma Wend. By HILIC separation and HRMS Detection.Colloidal characteristics and formulation of pure protein particulate vaccines
P2860
Q28073401-7542E7E3-8AD3-4054-B370-F176FB40F883Q33405446-A67BEBF6-6A1F-40AC-868D-D8B02982D799Q33721641-55389EAD-4510-4BA4-8F61-3FBF9D12D415Q35091726-0FE60DEF-70D1-49C4-BD7F-55C6791272C7Q35456892-C1754D61-49A9-4003-A94C-18D85DD6490CQ35859313-86393F4D-2F8A-437B-904C-C954C7035D77Q36073600-6954C69E-411E-4124-B173-B0F6FC54CD77Q36590168-750FA7E1-D469-4298-AF3E-D6219EE919CBQ36615170-D854723A-5862-44C4-A272-E35507526CB4Q36861211-511D2450-20ED-411B-8806-9429C6610C87Q36899084-1C5C52B9-38B1-43E5-A8E1-CA537873F2A2Q37259642-D122C318-7C10-43C3-ABE6-50D540169D58Q37354182-059DBC0D-F409-477F-95C5-3E1919A800DCQ37939609-642A3CA2-D3F7-44A8-9071-36EDCDC5DD9EQ38008360-D99CC01C-87D2-4446-AB64-D4D4E24456ECQ38105259-15A1859F-6017-41EA-A327-2FAF0282D8CBQ38270630-4AA12C2C-BAA0-4ACE-939C-A258A5EFD2D6Q38461061-98FA0FBF-1908-4E36-BEF7-5F3DBD2F9A9AQ38587300-734DD1C7-456A-4E03-8B9F-999E96A9846BQ38959949-AD0D3163-A72A-4E4B-A4FC-0B393CE38546Q38991313-8DB0ED73-EFFD-4B2E-9292-59A5C85F4F6FQ39169219-31A81CED-E74E-446F-8F17-19F0C0EF4927Q41884496-240C18CF-6E62-4146-AD07-D73B9B9AF3A5Q41912913-F8EA0388-FAF6-4F2E-98B5-B682F639D84AQ42648117-FFC7B082-7E9A-473B-83F3-3056C27E5C48Q43236610-5C30294A-4928-4F09-A638-A76D322B2861Q43237764-916D61ED-764B-4D52-8AA4-1255C82ED908Q46816112-1DA1E729-F9F8-4210-B47F-4BDD5A6C1E41Q47146365-F9C5601C-C377-4E92-9392-CA45F4375C59Q47149204-9E1068C8-6906-4B21-B79F-C71CB6CC7414Q47221063-B7A98A92-775F-4CCB-ADBE-836494CC8515Q47330307-2F9C4A25-DFF4-48C7-AFDC-EFF4C6BE49A4Q57835957-471A1872-5021-4F65-BF31-91D0D1D67153
P2860
Saponin-adjuvanted particulate vaccines for clinical use.
description
2006 nî lūn-bûn
@nan
2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Saponin-adjuvanted particulate vaccines for clinical use.
@ast
Saponin-adjuvanted particulate vaccines for clinical use.
@en
type
label
Saponin-adjuvanted particulate vaccines for clinical use.
@ast
Saponin-adjuvanted particulate vaccines for clinical use.
@en
prefLabel
Saponin-adjuvanted particulate vaccines for clinical use.
@ast
Saponin-adjuvanted particulate vaccines for clinical use.
@en
P1433
P1476
Saponin-adjuvanted particulate vaccines for clinical use
@en
P2093
Caroline D Skene
P356
10.1016/J.YMETH.2006.05.019
P577
2006-09-01T00:00:00Z